Skip to main content
Clinical Trials/CTRI/2020/04/024644
CTRI/2020/04/024644
Not yet recruiting
Phase 4

A Prospective Multi-centre, Non-interventional, observational Post Marketing Surveillance (PMS) Study of AdaliRelTM (Adalimumab) to Evaluate long-term safety in Patients With Active Rheumatoid arthritis in Routine Clinical Practice

Reliance Life Sciences Pv Ltd0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Reliance Life Sciences Pv Ltd
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Reliance Life Sciences Pv Ltd

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Rheumatoid Arthritis according to the criteria based on American College of Rheumatology (ACR)/ European League against Rheumatism (EULAR) classification criteria for Rheumatoid Arthritis according to routine clinical practice

Exclusion Criteria

  • 1\.Pregnant women, nursing mothers or a planned pregnancy within 18 months of selection.Allergy to any of the excipients of adalimumab.Active TB. Also excluded are patients who have evidence of latent TB \[evidence of tuberculosis based on standard hospital practice of TB screening]. Also excluded are patients with opportunistic infections including, but not limited to, evidence of active cytomegalovirus, active pneumocystis carinii, aspergillosis, or atypical mycobacterial infection, etc., within the previous 6 months.Patients with warnings / contraindications to AdaliRel® (see warnings in full prescribing information in Appendix )

Outcomes

Primary Outcomes

Not specified

Similar Trials